The QP Review Isn't the Bottleneck — Package Assembly Is
GDP-compliant IMP release requires a qualified person to review temperature excursion status, chain of custody, and regulatory compliance documentation before a shipment is cleared for site delivery. The QP's review itself is typically fast. What creates the 72-hour backlog is the time required to locate and assemble the supporting documentation from Controlant, Sensitech TempTale, SAP, and Veeva Vault — before the QP can make a decision.
Pre-Assembled Release Packages Ready for QP Review on Delivery
A clinical supply release agent reads real-time temperature data from Controlant and logger records from Sensitech TempTale, retrieves chain of custody documentation from SAP S/4HANA, and assembles a GDP-compliant pre-release package in Veeva Vault when a shipment arrives at a clinical site. The qualified person opens a complete, structured release package and issues approval or excursion escalation — without hunting across four systems. The target is QP review and release within 2 hours of delivery, down from the current 72-hour average.
Faster Release, Fewer Delays to Patient Dosing, Lower Escalation Risk
This is a risk and operational continuity story with a direct patient impact dimension. A 70-hour reduction in QP review backlog means clinical sites receive dosing supplies on schedule, protocol deviation risk from supply delays drops, and the QP team's capacity is freed for review work rather than document assembly. The efficiency reduction in manual package preparation runs 65–85%. The agent is live and handling shipment releases in approximately 5 weeks — long enough to configure integrations across Controlant, Sensitech, SAP, and Veeva to meet your specific GDP and FDA 21 CFR requirements.
What happens if a temperature excursion is detected in the Controlant or Sensitech data?
The agent flags the excursion in the pre-release package, includes the relevant logger data and excursion window, and routes the shipment for escalation review rather than standard release. The QP receives a clearly flagged exception package rather than a routine release request.
Is the assembled release package compliant with ICH, FDA 21 CFR, and EMA GDP requirements?
The package structure is built to your organization's GDP-compliant release documentation requirements, as defined during implementation. The agent generates the package; compliance validation and QP sign-off remain human responsibilities.